Cur oral administration is well tolerated with biological activity in pancreatic cancer, in spite of the limited absorption. Cur downregulated the cyclooxygenase-2, NF-κB, phosphorylated signal transducer in patients. The trial had positive outcomes with tumor regression and enhanced serum cytokines levels. Here, NFKB1 is linked to familial pancreatic carcinoma.